Mr. Finley is an experienced financial executive, having played instrumental roles in raising nearly $1 billion in capital for companies as both an internal Chief Financial Officer (CFO) and an independent investment banker. Prior to joining Palisade Bio (formerly Leading BioSciences) as the company’s CFO, Mr. Finley was the Chief Executive Officer, President and CFO for PointAcross, Inc., a software company providing business messaging and communications services. Mr. Finley previously co-founded Proteus Capital Partners, Inc., a firm specializing in providing financing for a variety of businesses, and was a Principal and CFO at Phillips Capital, a broker/dealer firm specializing in private debt and equity capital raises. During his career, he also served as Executive Vice President and CFO of MetroGolf, Inc., where he successfully completed MetroGolf’s initial public offering and was instrumental in growing the start-up company to over 125 employees. Mr. Finley began his business career as a tax specialist with Deloitte & Haskins and Sells (now Deloitte LLP), and later was co-owner of Mitchell Finley & Company, a full-service accounting firm.

Mr. Finley earned a Bachelor’s degree in Business Administration from Boise State University and a Master’s degree in Taxation from the University of Denver.

Dr. Mitch Jones is an accomplished physician and executive with extensive experience in the development of innovative therapeutics for inflammatory and fibrotic diseases. As Chief Medical Officer at Palisade Bio, Dr. Jones oversees all clinical development programs, regulatory strategies, and medical affairs, ensuring the advancement of the company’s pipeline in inflammatory, autoimmune and fibrotic disease.

Dr. Jones has a distinguished track record of advancing innovative therapies from translational research through clinical development and achieving regulatory approvals. He most recently served as Vice President of Corporate Development & Strategy at Chemomab Therapeutics, where he directed corporate strategy, program development, and strategic partnerships. His efforts were instrumental in advancing Chemomab’s clinical-stage programs and supporting the company’s financing and M&A activities.

Prior to Chemomab, Dr. Jones held key leadership roles at Finch Therapeutics and Biora Therapeutics (formerly Progenity). At Finch Therapeutics, he was Vice President of Clinical Discovery and Development, contributing to the company’s IPO and the early clinical development of novel therapeutics for IBD, chronic hepatitis B, and solid tumor immunotherapy. At Biora Therapeutics, he served as Vice President of Innovation and Clinical Translational Development, where he lead the development of the company’s technology platforms including Navicap™ and Biojet™, executed early clinical development and proof of efficacy studies, created strategic roadmaps and played a pivotal role in securing $125 million in venture financing and leading the company through its IPO. His early role within the company was building the GI therapeutics division as Vice President of Translational and Clinical Development.

Dr. Jones founded Interface Therapeutics, where he developed a novel sampling platform for multi-omics analysis of GI tract samples, leading to the discovery of locally acting therapeutics for IBD. Interface Therapeutics was later acquired by Biora Therapeutics. Earlier in his career, he founded Micropharma, where he developed the FDA-approved product LRC™, now sold globally by Chr. Hansen, and achieved regulatory approvals for microbiome-based therapeutics for metabolic and inflammatory diseases.

Dr. Jones is an inventor on nearly 200 patents and has authored numerous scientific publications. He holds MD and PhD degrees.

Mr. Willie has served as Senior Vice President, Finance and Corporate Controller of Palisade Bio since February of 2023 and previously served as Vice President, Finance and Corporate Controller. Prior to joining Palisade Bio, Mr. Willie held various senior roles at PricewaterhouseCoopers, LLP where he provided key assurance services to clinical-stage biotechnology companies as they navigated the complexities of international collaborations, clinical trials, and follow-on offerings.

Mr. Willie earned a Master’s degree in Accountancy and Bachelor’s degree in Accounting from Brigham Young University and is a Certified Public Accountant (inactive) in the state of California.

Ms. Skare brings more than 24 years of leadership experience in global clinical development and operations across large and emerging biotechnology companies. Her expertise spans autoimmune, metabolic, gastrointestinal, and fibrotic diseases, with a track record of successfully delivering programs from early development through regulatory approval, commercialization, and post-marketing submissions. She has served seven years as a department head within Clinical Operations and has been instrumental in multiple global inspection-readiness initiatives and post-approval filings for therapies in ulcerative colitis and diabetes. Ms. Skare most recently served as Vice President and Global Head of Clinical Operations at Abivax, where she oversaw global Phase 3 and Phase 2 programs in ulcerative colitis and Crohn’s disease. Previously, Ms. Skare held senior leadership positions at Pfizer and Arena Pharmaceuticals, where she led the global clinical operations program for Etrasimod, an oral, selective S1P receptor modulator for ulcerative colitis, now approved as Velsipity™. She earned Pfizer’s Craig A. Saxton Clinical Development Excellence Award and 12 additional company recognitions for clinical development excellence and operational leadership. Sharon served as head of clinical operations at Elcelyx Therapeutics, advancing a delayed-release metformin formulation for Type 2 diabetes from proof of concept through End-of-Phase 2 alignment with the FDA. Early in her career Ms. Skare was part of the core clinical operations and clinical science teams at Amylin Pharmaceuticals through the development and approval of Byetta®, the first GLP-1 agonist, and Symlin®, the first non-insulin treatment indicated for Type 1 diabetes. She also held clinical research roles at PPD and Clinimetrics Research Associates.

 Dr. Heyer is an accomplished leader in Translational Science, Translational Medicine, and Clinical Research with over two decades of experience in the pharmaceutical industry. Throughout his career he has played a pivotal role in the successful development and strategic management of multiple clinical drug programs including: FOTIVDA^® (tivozanib), a next-generation VEGFR TKI approved by the FDA in March 2021 for the treatment of adults with relapsed or refractory advanced renal cell carcinoma (RCC); Ficlatuzumab which is a potent, humanized IgG1 monoclonal antibody that targets HGF and is now tested in Phase 3 for HPV negative R/M HNSCC; CP101 which is a Phase 3, investigational, microbiome candidate in recurrent CDI; FN211 which is in Phase 1 for Autism Spectrum Disorder; and DCSZ11/DCBY02 fully humanized anti-CD93 antibodies regulating vascular normalization. In addition, Dr. Heyer worked on various preclinical molecules (i.e PDE4A inhibitor MEM1414) for neurodegeneration and Asthma. His contributions in drug development to disease modeling, gene expression profiling, histology, NGS and Translational Research have been documented in publications, presentations, patents and regulatory filings.

Dr. Heyer received his postdoctoral training at Albert Einstein College of Medicine in Human Genetics following receipt of his Ph.D. in Human Genetics from Julius Maximillians University in Wuerzburg Germany.

Dr. Izanec is a physician–scientist with over two decades of clinical and drug development leadership spanning immunology, neuroscience, and gastroenterology. He brings extensive experience directing registrational Phase 2 and Phase 3 programs, shaping asset-level development strategies, and guiding cross‑functional execution at leading pharmaceutical organizations including Bristol Myers Squibb and Janssen.

Prior to joining Palisade Bio, Dr. Izanec served as Senior Medical Director and Clinical Development Lead at Bristol Myers Squibb, where he led global Phase 2/3 development programs across autoimmune and neurological diseases. His responsibilities included oversight of a 1,200‑patient Phase 3 Crohn’s program, leadership of pediatric development programs in Crohn’s disease, ulcerative colitis, and multiple sclerosis, and strategic ownership for the clinical development plans of ozanimod and deucravacitinib.

Previously, he served as Medical Director at Janssen, where he led global Phase 3 and Phase 4 studies in gastroenterology and immunology, contributed to lifecycle and label‑expansion programs for ustekinumab and infliximab, and helped support the successful launch of Stelara in ulcerative colitis, the largest franchise within Johnson & Johnson.

Earlier in his career, Dr. Izanec spent a decade as a practicing gastroenterologist and hepatologist, serving as principal investigator for more than 50 clinical trials across inflammatory bowel disease,

hepatology, functional GI disorders, and motility disorders. He has authored more than 100 peer‑reviewed publications and abstracts and has been a frequent invited speaker at global medical congresses including DDW, ECCO, ACG, and UEGW.

Dr. Izanec received his medical degree from Weill Cornell Medical College, completed his internal medicine residency at Temple University Hospital, and his gastroenterology fellowship at Drexel University College of Medicine. He is a Fellow of the American Gastroenterological Association and graduated magna cum laude from Cornell University.